Back to Archived News
Lipid Sciences Granted Second HDL Selective Delipidation Patent
Tuesday, May 27, 2008
Strong IP Position Supports Business Development Initiative
Lipid Sciences, Inc. (Nasdaq: LIPD) announced the issuance of a second patent covering the Company's HDL Selective Delipidation technology. U.S. Patent No. 7,375,191 further extends Lipid Sciences' ownership over therapeutic HDL compositions provided by the Company's proprietary extracorporeal delipidation process. This new patent, together with Patent No. 7,361,739 issued on April 22, 2008, creates a broad ownership position in this important therapeutic space. The Company plans to capitalize on this strong IP position and recent encouraging clinical trial data by aggressively pursuing ongoing partnership discussions supporting commercialization of this promising medical technology.
Lipid Sciences' Selective Delipidation technology removes lipids from a patient's own HDL and then the delipidated HDL particles are returned to the patient. The delipidation process "energizes" these HDL particles enabling them to pick up excess lipids from plaque in the arterial walls and transport those lipids to the liver where they are processed and excreted naturally from the body. This important biological process is known as reverse cholesterol transport.
Dr. S. Lewis Meyer, President and Chief Executive Officer of Lipid Sciences, commented, "HDL therapy clearly represents the new frontier in the treatment of cardiovascular disease. Coronary heart disease continues to be the leading cause of death in the United States as well as in many countries around the world. HDL Selective Delipidation has the potential to be a safe, cost-effective solution to this significant clinical challenge. We believe we are uniquely positioned to be the first to market in HDL therapy."
Lipid Sciences, Inc. is a development-stage biotechnology company engaged in the research and development of products and processes intended to treat major medical indications, in which lipids, or fat components, play a key role. The Company's HDL Therapy platform (HDL Mimetic Peptides and HDL Selective Delipidation) aims to develop treatments to reverse atherosclerosis, a systemic disease caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. Regression of such plaques may have a major impact on reducing the risk of acute coronary events. The Company's Viral Immunotherapy platform focuses on the removal of the lipid coatings from lipid-enveloped viruses and other lipid-containing infectious agents by applying Lipid Sciences' proprietary delipidation technologies. The Company believes that removing the virus' protective lipid coating enhances the processing and presentation of viral proteins to stimulate the body's immune system to effectively fight the disease. Conditions that could potentially be impacted by these technologies include HIV, SARS, and influenza. In addition, Lipid Sciences believes that this Viral Immunotherapy platform also has applicability to a wide range of viruses impacting animal health -- a diverse market with diseases affecting both food and companion animals.
This release contains forward-looking statements concerning plans, objectives, goals, strategies, study results, anticipations, expectations, future events or performance as well as all other statements that are not statements of historical fact. The forward-looking statements contained in this release reflect our current beliefs and expectations on the date of this release. Actual results, performance or outcomes may differ materially from what is expressed in the forward-looking statements. Readers should refer to the documents filed by us with the SEC, specifically the most recent reports on Form 10-K and Form 10-Q which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. In addition to those risk factors, other factors that could cause actual results to differ materially include the following: our inability to obtain adequate funds; our technologies not proving to be safe or effective; our inability to obtain regulatory approval of our technologies, which are only in the clinical development stage; delay or failure to complete clinical studies; our dependence on our license agreement with Aruba International B.V.; our reliance on collaborations with strategic partners and consultants; our reliance on key suppliers to provide the material necessary to conduct successful pre-clinical and clinical studies; competition in our industry, including the development of new products by others that may provide alternative or better therapies; failure to secure and enforce our intellectual property rights; risks associated with use of biological and hazardous materials; acceptance of our potential products by healthcare providers and patients; and our dependence on key personnel.
This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov. Lipid Sciences assumes no obligation to update the forward-looking statements included in this document.
Press releases for Lipid Sciences, Inc. are available on our website: www.lipidsciences.com. To receive the Company's press releases via email, please contact: email@example.com.
Back to Archived News